sunitinib,ibrutinib,pacritinib,ponatinib,gilteritinib,sorafenib,crenolanib,quizartinib
pfizer,arog,astellas,abbvie,takeda,janssen,otsuka,cti biopharma,daiichi sankyo,bayer,incyte
['ponatinib', ' ibru', 'sunitinib', 'crenolanib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'quizartinib', 'gilteritinib', 'sorafenib', 'pacritinib']
#ash22.finally some #gilteritinib data in upfront setting from #japan. adults receiving #gilteritinib as maintenance post+hsct had 100% lfs vs 36% at 1 yr, even in those with mrd+ status. small study but imp findings for #flt3aml. flt3 inhibitor space is getting exciting! 
Pediatric Hemato-Oncologist, BMT physician, PGIMER Chandigarh alumnus, passionate about #ChildHealth, #leukemias #BMT #PID